Everest Organics Ltd
NSE: BSE: 524790
₹252
(0.40%)
Sat, 30 May 2026, 09:49 am
Market Cap2.38B
PE Ratio41.97
Dividend0
Distribution Services
Medical Distributors
24.5KEverest Organics Analysis
dividend
- Dividends paid are thoroughly covered by earnings (9.9x coverage).
- Everest Organics's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Everest Organics only just started paying a dividend, it is too early to tell if payments are increasing.
- It is too early to tell whether Everest Organics has stable dividend payments.
- Everest Organics's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Everest Organics is profitable, therefore cash runway is not a concern.
- Everest Organics is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (49.5%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 3.2x debt.
- Everest Organics's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (448.7% vs 74% today).
- Interest payments on debt are well covered by earnings (EBIT is 8.9x coverage).
- Everest Organics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Everest Organics's level of debt (74%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Everest Organics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Srikakarlapudi's remuneration is about average for companies of similar size in India.
- Srikakarlapudi's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Everest Organics management team is about average.
misc
- Everest Organics is not covered by any analysts.
- Everest Organics has significant price volatility in the past 3 months.
past
- Everest Organics has delivered over 20% year on year earnings growth in the past 5 years.
- Everest Organics used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Everest Organics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Everest Organics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Everest Organics's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (29.7% vs 22.7%).
- Everest Organics's 1-year earnings growth is less than its 5-year average (29.7% vs 53.1%)
value
- Everest Organics is good value based on earnings compared to the IN Pharmaceuticals industry average.
- BSE:524790 is up 34.4% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524790 is up 34.4% outperforming the market in India which returned 8% over the past month.
- Everest Organics's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Everest Organics's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Everest Organics is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Everest Organics is overvalued based on earnings compared to the India market.
- 524790 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524790 underperformed the Market in India which returned -14.5% over the past year.